Review · United States
BPC-157
Reviewed on
Approval and product status
Still being studied; no FDA-approved BPC-157 product identified
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
What was measured in people?
- Health results · Limited
- Small uncontrolled pilots cannot establish a patient benefit.
- Body changes · Limited
- Human exposure and pharmacokinetic characterization remain sparse.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
Still unknown: The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
Read all BPC-157 fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 7 sources
- July 2026 PCAC briefing on BPC-157-related bulk drug substances
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- Certain bulk drug substances for use in compounding that may present significant safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- BPC-157 as an investigational peptide therapeutic: translational development barriers
PubMed · Pharmaceutics · Science review · 2026
Source accessed
- Safety of intravenous infusion of BPC157 in humans: a pilot study
PubMed · Alternative Therapies in Health and Medicine · Human pilot · 2025
Source accessed
- Promoting effect of BPC 157 on tendon healing: tendon outgrowth, cell survival, and migration
PubMed · Journal of Applied Physiology · Preclinical · 2011
Source accessed
- 2026 prohibited list
World Anti-Doping Agency · Anti-doping · 2026
Source accessed
- BPC 157 for acute hamstring muscle strain repair
ClinicalTrials.gov · Trial registry · 2026
Source accessed